{"prompt": "['Protocol RS-001', 'Confidential', '88.', 'Swiech, L., et al., Role of mTOR in physiology and pathology of the nervous system.', 'Biochim Biophys Acta, 2008. 1784(1): p. 116-32.', '89.', 'Hoeffer, C.A. and E. Klann, mTOR signaling: at the crossroads of plasticity, memory and', 'disease. Trends Neurosci, 2010. 33(2): p. 67-75.', '90.', 'Garelick, M.G. and B.K. Kennedy, TOR on the brain. Exp Gerontol, 2011. 46(2-3): p.', '155-63.', '91.', 'Chang, N., et al., Phosphatase PTEN in neuronal injury and brain disorders. Trends', 'Neurosci, 2007. 30(11): p. 581-6.', '92.', 'Fingar, D.C., et al., Mammalian cell size is controlled by mTOR and its downstream', 'targets S6K1 and 4EBP1/eIF4E. Genes Dev, 2002. 16(12): p. 1472-87.', '93.', 'Fingar, D.C., et al., mTOR controls cell cycle progression through its cell growth', 'effectors S6K1 and 4E-BPl/eukaryotic translation initiation factor 4E. Mol Cell Biol,', '2004. 24(1): p. 200-16.', '94.', 'Zhang, H.H., et al., S6K1 regulates GSK3 under conditions of mTOR-dependent feedback', 'inhibition of Akt. Mol Cell, 2006. 24(2): p. 185-97.', '95.', 'Inoki, K., et al., TSC2 integrates Wnt and energy signals via a coordinated', 'phosphorylation by AMPK and GSK3 to regulate cell growth. Cell, 2006. 126(5): p. 955-', '68.', '96.', 'Ma, T., et al., Dysregulation of the mTOR pathway mediates impairment of synaptic', \"plasticity in a mouse model of Alzheimer's disease. PLoS One, 2010. 5(9).\", '97.', 'Harada, H., et al., p70S6 kinase signals cell survival as well as growth, inactivating the', 'pro-apoptotic molecule BAD. Proc Natl Acad Sci U S A, 2001. 98(17): p. 9666-70.', '98.', 'Dunlop, E.A. and A.R. Tee, Mammalian target of rapamycin complex 1: signalling', 'inputs, substrates and feedback mechanisms. Cell Signal, 2009. 21(6): p. 827-35.', '99.', 'Inghirami, G., et al., New and old functions of STAT3: a pivotal target for individualized', 'treatment of cancer. Cell Cycle, 2005. 4(9): p. 1131-3.', '100.', 'Kisseleva, T., et al., Signaling through the JAK/STAT pathway, recent advances and', 'future challenges. Gene, 2002. 285(1-2): p. 1-24.', '101.', 'Masri, J., et al., mTORC2 activity is elevated in gliomas and promotes growth and cell', 'motility via overexpression of rictor. Cancer Res, 2007. 67(24) p. 11712-20.', '102.', 'Sparks, C.A. and D.A. Guertin, Targeting m TOR: prospects for mTOR complex 2', 'inhibitors in cancer therapy. Oncogene, 2010. 29(26): p. 3733-44.', '103.', 'Sarbassov, D.D., et al., Prolonged rapamycin treatment inhibits mTORC2 assembly and', 'Akt/PKB. Mol Cell, 2006. 22(2): p. 159-68.', '104.', 'Huang, J. and B.D. Manning, The TSC1-TSC2 complex: a molecular switchboard', 'controlling cell growth. Biochem J, 2008. 412(2): p. 179-90.', '105.', 'Otani, H., et al., Involvement of protein kinase C and RhoA in protease-activated receptor', '1-mediated F-actin reorganization and cell growth in rat cardiomyocytes. J Pharmacol', 'Sci, 2011. 115(2): p. 135-43.', '106.', 'Hu, Z.L., et al., Disruption of PICKI attenuates the function of ASICs and PKC', 'regulation of ASICs. Am J Physiol Cell Physiol, 2010. 299(6): p. C1355-62.', '107.', 'Herring, D., et al., PKC modulation of GABAA receptor endocytosis and function is', 'inhibited by mutation of a dileucine motif within the receptor beta 2 subunit.', 'Neuropharmacology, 2005. 48(2): p. 181-94.', '108.', 'Poisbeau, P., et al., Modulation of synaptic GABAA receptor function by PKA and PKC', 'in adult hippocampal neurons. J Neurosci, 1999. 19(2): p. 674-83.', 'Version 2', 'Version Date: October 31, 2018', 'Page 67 of 72']['Protocol RS-001', 'Confidential', '109.', 'Yasuda, K., et al., PKC-dependent inhibition of CA2+-dependent exocytosis from', 'astrocytes. Glia, 2011. 59(1): p. 143-51.', '110.', 'Bruhn, M.A., et al., Second AKT: the rise of SGK in cancer signalling. Growth Factors,', '2010. 28(6): p. 394-408.', '111.', 'Wu, P. and Y.Z. Hu, PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on', 'clinical progress. Curr Med Chem, 2010. 17(35): p. 4326-41.', '112.', 'Huang, X., et al., Pharmacological inhibition of the mammalian target of rapamycin', 'pathway suppresses acquired epilepsy. Neurobiol Dis, 2010. 40(1): p. 193-9.', '113.', 'Buckmaster, P.S., E.A. Ingram, and X. Wen, Inhibition of the mammalian target of', 'rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent', 'model of temporal lobe epilepsy. J Neurosci, 2009. 29(25): p. 8259-69.', '114.', 'Zeng, L.H., N.R. Rensing, and M. Wong, The mammalian target of rapamycin signaling', 'pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci, 2009.', '29(21): p. 6964-72.', '115.', 'Meikle, L., et al., Response of a neuronal model of tuberous sclerosis to mammalian', 'target of rapamycin (mTOR) inhibitors: effects on mTORCI and Akt signaling lead to', 'improved survival and function. J Neurosci, 2008. 28(21): p. 5422-32.', '116.', 'Di Nardo, A., et al., Tuberous sclerosis complex activity is required to control neuronal', 'stress responses in an mTOR-dependent manner. J Neurosci, 2009. 29(18) : p. 5926-37.', '117.', 'Ljungberg, M.C., et al., Rapamycin suppresses seizures and neuronal hypertrophy in a', 'mouse model of cortical dysplasia. Dis Model Mech, 2009. 2(7-8): p. 389-98.', '118.', 'Zeng, L.H., et al., Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis', 'complex. Ann Neurol, 2008. 63(4): p. 444-53.', '119.', 'Zou, L., et al., [Efficacy and safety of rapamycin in treatment of children with epilepsy', 'complicated with tuberous sclerosis]. Zhonghua Er Ke Za Zhi, 2014. 52(11): p. 812-6.', '120.', 'Krueger, D.A., et al., Everolimus for subependymal giant-cell astrocytomas in tuberous', 'sclerosis. N Engl J Med, 2010. 363(19): p. 1801-11.', '121.', 'Franz, D.N., et al., Everolimus for subependymal giant cell astrocytoma in patients with', 'tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-I', 'study. Lancet Oncol, 2014. 15(13): p. 1513-20.', '122.', 'Franz, D.N., et al., Long-Term Use of Everolimus in Patients with Tuberous Sclerosis', 'Complex: Final Results from the EXIST-1 Study. PLoS One, 2016. 11(6): p. e0158476.', '123.', 'Bissler, J.J., et al., Everolimus long-term use in patients with tuberous sclerosis complex:', 'Four-year update of the EXIST-2 study. PLoS One, 2017. 12(8): p. e0180939.', '124.', 'French, J.A., et al., Adjunctive everolimus therapy for treatment-resistant focal-onset', 'seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-', 'blind, placebo-controlled study. Lancet, 2016. 388(10056): p. 2153-2163.', '125.', 'Samueli, S., et al., Efficacy and safety of Everolimus in children with TSC - associated', 'epilepsy - Pilot data from an open single-center prospective study. Orphanet J Rare Dis,', '2016. 11(1) p. 145.', '126.', 'Krueger, D.A., et al., Long-term treatment of epilepsy with everolimus in tuberous', 'sclerosis. Neurology, 2016. 87(23): p. 2408-2415.', '127.', 'Aguilera, D., et al., Response of subependymal giant cell astrocytoma with spinal cord', 'metastasis to everolimus. J Pediatr Hematol Oncol, 2014. 36(7): p. e448-51.', '128.', 'Mingarelli, A., et al., Dramatic relapse of seizures after everolimus withdrawal. Eur J', 'Paediatr Neurol, 2017.', 'Version 2', 'Version Date: October 31, 2018', 'Page 68 of 72']\n\n###\n\n", "completion": "END"}